Caris Life Sciences (CAI) Receivables - Net (2024 - 2026)

Caris Life Sciences has reported Receivables - Net for 3 years, with the latest figure at $116.9 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 129.69% year-over-year to $116.9 million in Q2 2026; TTM through Jun 2026 was $116.9 million, a 129.69% increase from a year earlier, with the FY2025 full-year figure at $112.1 million, up 27.08% from the prior year.
• Receivables - Net was $116.9 million for Q2 2026 at Caris Life Sciences, up from $90.5 million in the prior quarter.
• The five-year high for Receivables - Net was $116.9 million in Q2 2026, with the low at $26.7 million in Q3 2025.
• Average Receivables - Net over 3 years is $80.9 million, with a median of $89.4 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net gained 27.08% in 2025, then surged 129.69% in 2026.
• Over 3 years, Receivables - Net stood at $88.2 million in 2024, then rose by 27.08% to $112.1 million in 2025, then increased by 4.23% to $116.9 million in 2026.
• The last three Receivables - Net figures came in at $116.9 million (Q2 2026), $90.5 million (Q1 2026), and $112.1 million (Q4 2025), per Business Quant data.